SPARC announces sale of its Rare Paediatric Disease Priority Review Voucher for US $195 million through a definitive asset purchase agreement.
The PRV was granted by the FDA for the approval of Sezaby® used for treatment of neonatal seizures.
CEO stated proceeds will accelerate pipeline development and strengthen external innovation strategy.
Transaction is subject to customary closing conditions including HSR Antitrust Act waiting period expiration.